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INTRODUCTION
In the animal body the formation of new cells requires the synthesis of
nucleic acids and for this purpose certain derivatives of pyrimidine bases
(e.g., uracil, cytosine, and thymine) must be synthesized by, or supplied to,
the parent cells. Accordingly, it would be reasonable to assume that sig-
nificant interference with the formation or utilization of these pyrimidine-
containing compounds could profoundly affect the rate at which new cells
are formed in various tissues. It is often assumed that a potent inhibitor of
cellular reproduction should affect all tissues in a comparable manner;
however, many factors influence to a variable degree the capacity of a com-
pound to disturb the reproduction of various types of cells in a variety of
tissues. Indeed, the moderate degree of selectivity already observed with
certain well-recognized carcinostatic agents is indicative of significant vari-
ability, in different loci, in such factors as transport into cells, affinity for
those enzymes which normally react with physiological intermediates,
and the degree of metabolic alteration of such agents.
The results of earlier studies from these laboratories of the biological
effects of analogs of the naturally occurring pyrimidines, orotic acid,' "'
thymine, and its deoxyriboside,6"7"8 encouraged us to attempt to obtain a
compound capable of interfering specifically with the metabolism of uracil-
containing substances. Such a compound (or appropriate derivatives of it)
could interfere not only with the synthesis of ribonucleic acids, but also
with that of deoxyribonucleic acids, and with a sizable group of coenzymes
containing either uracil or its derivative, cytosine.
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For this purpose a most promising possibility, as suggested by earlier
studies of 6-azathymine (6-methyl-as-triazine-3,5-dione) and its deoxyribo-
side,'17,8 was a comparable analog of uracil, namely, 6-azauracil (as-
triazine-3,5-dione), a substance with chemical structure and stability which
made pertinent its biological investigation. Although prepared in 1947 for
use in a study of chemical reaction mechanisms, the method of synthesis was
not described in detail,20 and, therefore, a new procedure was evolved."'
Studies by Handschumacher and Welch" of the effect of 6-azauracil
(AzU) on a variety of microorganisms indicated that this analog is an
effective inhibitor of cellular reproduction and that its action under certain
conditions can be nullified by the natural metabolites: uracil and uridine
(uracil riboside). Of especial significance to further applications of the
analog was the finding that the utilization not only of exogenous, but also
of endogenously formed derivatives of uracil was blocked by the antagonist.
It has been shown that with Streptococcus faecalis 8043, an organism
highly susceptible to inhibition by AzU, drug-resistant mutants are selected
by AzU." The mechanism of this resistance is attributed' to the fact that
among a significant population of S. faecalis cells there are individuals
which possess no capacity to utilize free uracil and thus offer no pathway for
the assimilation of AzU. Since such AzU-resistant cells can utilize uridine,
it was reasoned that biochemical circumvention of this type of drug-
resistance should be possible through the use of AzU-riboside (AzUR).
This compound, azauridine, was prepared both biologically and chemically9
and shown to be highly inhibitory to AzU-resistant bacteria. It should be
mentioned, however, that resistance to AzUR also can be encountered in
bacterial populations. Evidence that AzU enters the same pathways of
metabolism as does uracil or uridine has been shown by the isolation from
the acid-soluble fraction of microorganisms exposed to AzU-C14 of radio-
active azauridine and its mono-, di-, and tri-phosphates; in addition, other
derivatives of AzU are formed in small amounts.9"0
Tests of AzU in mice bearing various transplantable neoplasms, carried
out collaboratively at Yale and the National Cancer Institute (Law), and
also, independently, at the Wellcome Physiological Laboratories and in
Czechoslovakia, showed that the analog, in doses exerting slight or no toxic
effects on the host, appreciably inhibited the growth of such tumors as
lymphomas L-1210, L-4946, L-5178, and sarcoma 180,' adenocarcinoma
755,2 Ehrlich ascites carcinoma,' and the plasma cell neoplasm 70429.'
Since the bacterial studies had suggested that inhibition of cellular repro-
duction requires the formation of ribose-containing derivatives of AzU,
tests were made of the urine of mice receiving AzU and the presence of
material behaving in all respects as AzUR was demonstrated.' Further-
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more, studies of sarcoma 180 cells reproducing in tissue culture showed
that, although quite unaffected by AzU (in concentrations up to 5 ,umoles/
ml.), the growth of the neoplastic cells was inhibited by AzUR (0.01-0.02
,umole/ml.), an effect prevented by uridine but not by uracil.' Even greater
sensitivity to AzUR was obtained with L-5178 in tissue culture; not only
were these cells insensitive to free AzU, but even to its deoxyriboside5 (the
latter compound was prepared biosynthetically from AzU).' In these cell-
systems,"0' and in S. faecalis,8 exposure of reproducing cells to AzUR-C14
led to extensive accumulation of radioactivity in the acid-soluble, but only
to a very limited degree, if at all, in the nucleic acid fractions.
Since the chemical synthesis of AzUR is tedious and gives unsatisfactory
yields, the conversion of AzU to AzUR was accomplished biologically using
S. faecalis,9 and, more recently, through the use of modifications of a ribo-
sidation procedure involving E. coli, described by Skoda et al.'
The present paper describes the remarkably higher activity of AzUR, in
comparison with AzU, as an inhibitor of the growth of the lymphomatous
neoplasms L-1210 and L-5178, and of sarcoma 180, in mice.
MATERIALS AND METHODS
The procedures used in these experiments have been described in detail elsewhere by
Mautner and Jaffe ; only enough information is given herein to make the data intelligi-
ble. Studies with the two lymphomas were done in AKR X DBA/2 F, hybrid mice of
either sex (Jackson Laboratories), while studies with sarcoma 180 were done in female
SWR mice (Millerton Research Farm); in both cases the animals were 6-8 weeks old,
weighed 18-25 g., and were given Purina Lab Chow and water ad libitum. Sarcoma
180, obtained aseptically from a donor mouse, was divided into pieces of about 1 mm.8;
one of these was implanted subcutaneously with a trocar into the right axillary region
of each mouse. The lymphomas were transferred subcutaneously (right flank) as a
suspension of cells; each mouse was given, within experimental error, the same number
of cells (1-3 X 106). The parent strains of both L-1210 and L-5178, obtained from
Lloyd Law of the National Cancer Institute, were carried in the ascitic form in
DBA/2 mice; in these experiments a special strain of the latter lymphoma termed
L-5178-Y was used.* &
Treatment, which began 24 hours after introduction of the neoplastic cells or tissue,
was given either intraperitoneally (0.5 ml.) at intervals of 8 hours or by way of the
drinking water (AzU: 0, 1.25, 2.5 and 5 mg./ml. (0, 11, 22, and 44 Atmoles/ml.),
respectively; AzUR: 0, 0.125, 0.25 and 0.5 mg./ml. (0, 0.5, 1.0 and 2.0 ,moles/ml.),
respectively). Therapy was terminated after 6 days with the lymphomas and after
7 days with S-180. On the following day the lymphomatous mice were weighed, sacri-
ficed, and the tumors carefully excised, weighed, and the weights compared with those
* The Y-strain of L-5178 was developed by G. A. Fischer and J. J. Jaffe from a
single cell isolated in vitro and grown in a medium which has been described by G. A.
Fischer and A. D. Welch (Science, 1957, 126, 1018-1019).
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of the tumors of untreated control mice; with the S-180 mice, the length of the two
largest perpendicular axes of the tumors was measured in situ (to 0.1 mm.) and the
tumor volume was estimated, using the formula for determining the volume of a prolate
spheroid, and the volumes obtained were compared to those of the tumors in the
untreated control mice. In Table 1 the results are presented in terms of mean values,
together with the standard error of each mean; the effectiveness of each dosage
regimen is indicated by the approximate percentage of inhibition of tumor growth.
RESULTS
The results obtained are summarized in Table 1. In addition, an experi-
ment was carried out to test the effect of frequency of administration of
AzUR on its efficacy. Earlier it had shown7 that AzU is maximally effective
against L-1210 lymphomas when given for 6 days in the drinking water or
when the total daily doses (15 mg./20-g. mouse/day) were given in three
portions at 8-hour intervals (83 per cent inhibition). If the same total
amount was given only once daily, the inhibition obtained was 41 per cent,
while administration twice daily, at intervals compatible with a normal
working day, 9 a.m. and 5 p.m., gave only 50 per cent inhibition. Since
other evidence indicated that AzUR is excreted even more rapidly than is
AzU,* the relation between frequency of dosage of AzUR and its degree of
carcinostatic effect was investigated (with L-5178-Y). It was found that
insignificant inhibitions of tumor growth were obtained when the drug was
given less frequently than at 8-hour intervals.
DISCUSSION
The data obtained from the comparative studies of the effect of AzUR
and AzU on the growth of mouse tumors L-1210, L-5178-Y and sarcoma
180 show clearly that, on a molar basis, the carcinostatic activity of the
riboside is from 10 to 20 times that of AzU.
Although the inhibitory effect of AzU on the growth of sarcoma 180 is
not dramatic, the effects of AzUR, in molar ratio of 1: 22 (AzUR: AzU),
were clearly as great or greater than were those of the free base. Also, with
L-1210 and L-5178-Y the comparisons of AzUR and AzU leave no doubt
concerning the far greater potency of AzUR as an inhibitor of the very
rapid growth of these lymphomas, which eventually cause a fatal leukemia.
It is believed that the limited capacity of the mouse to convert AzU to
* Preliminary experiments in collaboration with L. Peters and R. Volle, Department
of Pharmacology, University of Kansas, have shown that, in the hen, renal tubular
secretion contributes to the excretion of AzUR but not to that AzU. Preliminary
studies in man with S. C. Finch, Department of Internal Medicine, Yale University
School of Medicine, also have shown that AzUR is cleared more rapidly from the
blood and excreted more rapidly by the kidney than is AzU.
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ribose-containing derivatives, a reaction known to occur in the liver,'0 is
responsible for the fact that AzU exerts a carcinostatic effect, for the tumors
so far tested in tissue culture have not been affected by AzU per se, while
AzUR is highly inhibitory to the growth of those lines studied."'9 Since
the ability of individual animals to form active derivatives of AzU may be
variable, and may be influenced by dietary or many other factors, it would
seem preferable now to give attention to the possible applications of AzUR
as a carcinostatic agent, particularly in man. Another important reason for
avoiding the use of free AzU in man is its ability to cause manifestations of
central nervous system toxicity of varying degrees of severity when given
repeatedly during several days (1-45 mg./kg./day), an effect which so far
as is known is peculiar to the human species. First observede in collabora-
tion with D. H. Clement, this effect of AzU already has been studied exten-
sively by others (Shnider et al.'; Wells et al.'). Earlier studies of AzU in
dogs and monkeys had disclosed no effects on the central nervous system,
and the anesthetic effect seen in rats and mice is obtained only with enor-
mous dosages (3-5 grams of AzU per kg.).' Evidence already has been
obtained to indicate that the central effects observed in man probably are
not closely related to the narcotic activity of AzU observed in rodent
species.
Studies of the toxicity of AzUR, given at 8-hour intervals to dogs, are
now in progress. These have disclosed that the compound gradually de-
presses the total leucocyte count and eventually the platelet count without
causing, as yet, evidence of those profound disturbances of the formation
of new cells in the intestinal epithelium which have limited so greatly the
use of many other carcinostatic agents. No evidence of an effect of chroni-
cally administered AzUR on the central nervous system of dogs or mice
has been observed, except perhaps that the anorexia and resultant loss of
weight, seen at the higher dose-levels, may be the result of a central effect
of the compound. At present, it would appear that the potential usefulness
of AzUR as a carcinostatic agent, particularly as an anti-leukemic agent, or
as a possible inhibitor of the intracellular synthesis of various nucleic acid-
containing viruses, will depend to a considerable degree on the absence, or
the degree of severity, of undesirable effects on the central nervous system
of man. Investigations now in progress are designed to obtain answers to
this and related questions.
The rapid loss of unchanged AzUR from the blood and other tissues calls
attention to the remarkable stability of this riboside and to the effect of
ribosidation on the pathways of renal elimination of AzU. As is well known,
the physiologically occurring ribosides are readily cleaved by nucleosidases
and it is of considerable theoretical, as well as practical, interest that the
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enzymatically formed riboside of AzU, so closely analogous to uridine in
structure, is so very resistant to attack by catabolic enzyme systems. The
finding that ribosidation of AzU results in its more rapid removal from the
blood, because of active renal tubular secretion in the kidneys, is certain to
lead to studies of the effect on tubular secretion of ribosidation of other
bases either foreign to the body or of physiological significance. From the
more practical standpoint, investigation of the mechanism of the renal tubu-
lar secretion of AzUR might suggest a means of interfering with this path-
way which would permit a reduction in the rate at which the presently
exceedingly precious compound is lost from the blood and other tissues.
Finally, it may be stated that, should additional studies of AzUR offer
promise of chemotherapeutic utility, there is reason to believe that the
biological conversion of AzU to its riboside will be a practicable procedure,
the cost of which should not be a serious limitation on the continued
investigation of this new agent.
SUMMARY
Azauridine, the riboside of 6-azauracil, is shown to be a potent inhibitor
of the growth in mice of lymphomas L-1210 and L-5178-Y (a new strain
of L-5178), and of sarcoma 180. On a molar basis, azauridine is from 10 to
20 times as active as 6-azauracil, and, in the amounts required, exerts a
negligible host toxicity. The rapid elimination of azauridine in the urine
necessitates frequent administration of the compound, when given paren-
terally, but its remarkable stability and resistance to enzymatic degradation
permit azauridine to be given as effectively by mouth (in the drinking
water of mice) as by frequent parenteral injection.
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